Current disease status-Recurrent leukemia - Page 3 of 8 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent leukemia Posts on Medivizor

Blinatumomab vs chemotherapy in the treatment of relapsed or unresponsive acute lymphoblastic leukemia

Blinatumomab vs chemotherapy in the treatment of relapsed or unresponsive acute lymphoblastic leukemia

Posted by on Jun 23, 2019 in Leukemia | 0 comments

In a nutshell This study compared the safety and effectiveness of blinatumomab (Blincyto) with chemotherapy in the treatment of acute lymphoblastic leukemia (ALL). Researchers found the survival was higher with blinatumomab than chemotherapy alone. Some background Patients with unresponsive or relapsed ALL treated with chemotherapy have...

Read More

Looking for patients with Ph+ or BCR-ABL+ acute lymphoblastic leukemia to test a treatment combination

Posted by on Jun 14, 2019 in Leukemia | 0 comments

In a nutshell This phase 2 trial is evaluating the effectiveness of ponatinib (Iclusig) plus chemotherapy for patients with acute lymphoblastic leukemia (ALL) that is positive for the Philadelphia chromosome (Ph+) or the BCR-ABL gene (BCR-ABL+). The main outcome to be measured will be the number of patients who respond to treatment. This study is...

Read More

Outcomes of stem cell transplant for patients with acute lymphoblastic leukemia after inotuzumab ozogamicin treatment

Outcomes of stem cell transplant for patients with acute lymphoblastic leukemia after inotuzumab ozogamicin treatment

Posted by on Jun 5, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the outcomes of allogeneic stem cell transplant (allo-SCT) after treatment with inotuzumab ozogamicin (Besponsa) for patients with relapsed/unresponsive acute lymphoblastic leukemia (ALL). This study concluded that allo-SCT provided optimal long-term survival benefit for these patients. Some...

Read More

Looking for young patients with B-cell acute lymphoblastic leukemia to test a new T-cell therapy

Posted by on Apr 22, 2019 in Leukemia | 0 comments

In a nutshell This phase 2 trial is evaluating the effectiveness of huCART19 cell therapy in young patients with high-risk B-cell acute lymphoblastic leukemia (ALL). The main outcome to be measured will be survival without a treatment-related complication. This study is being conducted in Philadelphia, Pennsylvania, United States. The details Acute...

Read More

Searching for patients to try a new therapy for non-responsive leukemia/lymphoma after stem-cell transplant.

Posted by on Mar 15, 2019 in Leukemia | 0 comments

In a nutshell This study will investigate the effects of ibrutinib (Imbruvica) in patients with non-responsive leukemia/lymphoma after a stem-cell transplant. The main outcome that will be measured is the time after treatment before patients experience cancer worsening. This trial is recruiting in the United States. The details Some patients with...

Read More

Is entospletinib an effective treatment for relapsed or unresponsive chronic lymphocytic leukemia?

Is entospletinib an effective treatment for relapsed or unresponsive chronic lymphocytic leukemia?

Posted by on Mar 12, 2019 in Leukemia | 0 comments

In a nutshell This study examined if entospletinib can be used as a treatment for relapsed or unresponsive chronic lymphocytic leukemia (CLL). This study concluded entospletinib has disease reducing activity in patients with CLL, where previous treatment has failed. Some background Chronic lymphocytic leukemia (CLL) is a cancer of the bone marrow. It...

Read More

Effectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia

Effectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia

Posted by on Mar 9, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effectiveness of venetoclax (Venclexta) in the treatment of relapsed or unresponsive chronic lymphocytic leukemia (CLL). Researchers found venetoclax improved outcomes in these patients. Some background CLL is a cancer of the bone marrow. This may lead to an abnormal immune system. It is also often...

Read More

Comparing ibrutinib and ofatumumab in patients with previously treated chronic lymphocytic leukemia

Posted by on Jan 28, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate patient well-being and patient-reported outcomes in previously treated patients with chronic lymphocytic leukemia who receive ibrutinib (Imbruvica) or ofatumumab (Arzerra). They concluded that ibrutinib can improve quality of life while prolonging survival in these patients. Some background...

Read More

Searching for patients with relapsed or unresponsive acute myeloid leukemia to test a new treatment

Posted by on Jan 2, 2019 in Leukemia | 0 comments

In a nutshell This trial is examining the effectiveness of a new drug called uproleselan for patients with acute myeloid leukemia (AML). The main outcome to be measured will be overall survival. This study is being conducted in the United States. The details Acute myeloid leukemia (AML) is a cancer of the bone marrow. It leads to an abnormal immune...

Read More

Evaluating the use of ibrutinib with bendamustine and rituximab treatment in unresponsive chronic lymphocytic leukemia

Evaluating the use of ibrutinib with bendamustine and rituximab treatment in unresponsive chronic lymphocytic leukemia

Posted by on Dec 8, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the safety and effectiveness of ibrutinib (Imbruvica) added to bendamustine (Treanda) and rituximab (Rituxan) in the treatment of unresponsive chronic lymphocytic leukemia. Researchers found that this treatment improved survival in these patients. Some background Chronic lymphocytic leukemia (CLL) is a...

Read More